Editas Medicine announced the appointment of Linea Aspesi as the Company’s Executive Vice President, EVP, and Chief People Officer, CPO. Aspesi will lead Editas’ human resources department and the Company’s people strategy in support of its mission and goals. Aspesi joins Editas from Forma Therapeutics, where she served as Chief Human Resources Officer and successfully led the negotiations related to the people elements of the US $1B acquisition of Forma by Novo Nordisk in late 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
- Editas Medicine price target lowered to $22 from $35 at Chardan
- Editas Medicine price target lowered to $30 from $36 at Wells Fargo
- Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
- Editas Medicine reports Q4 EPS (88c), consensus (80c)